Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
URGN
#2445
UroGen Pharma Ltd. Ordinary Shares
21.220
0
USD
+4.64%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+4.64%
Changement Mensuel
+12.69%
Evolution sur 6 mois
+11.68%
Changement Annuel
+11.68%
Clôture Précédente
20.280
0
Open
21.220
0
Bid
Ask
Low
21.220
0
High
21.220
0
Volume
100
Marchés
Actions des Marchés US
Soins de Santé
URGN
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
48.68 M
—
Valuation ratios
Enterprise value
348.49 M
171.21 M
244.66 M
522.55 M
441.4 M
1.15 B
3.31 B
Price to earnings ratio
—
—
-1.79
-4.29
-3.6
-7.34
-20.71
Price to sales ratio
—
—
3.52
6.45
5.86
11.93
37.73
Price to cash flow ratio
—
—
-2.25
-5.74
-4.72
-6.94
-23.5
Price to book ratio
—
—
-2.21
-6.73
-51.87
-10.68
24.82
Enterprise value to EBITDA ratio
-2.75
-1.87
-2.86
-6.6
-4.05
-8.17
-23.78
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.77
-0.73
Return on equity %
-1.33
-13.17
1.23
1.57
14.41
1.46
2.02
Return on invested capital %
-1 304.03
-2 060.7
-1 538.17
-1 158.23
-1 526.09
-1 244.1
-1 789.5
Gross margin %
91.45
89.27
101.4
107.87
104.67
103.07
415.45
Operating margin %
-1 074.15
-192.11
-141.35
-96.38
-124.28
-132.21
-604.15
EBITDA margin %
-1 074.29
-190.38
-154.79
-116.84
-139.98
-149.57
-679.23
Net margin %
-1 088.94
-230.67
-196.33
-150.36
-162.92
-162.53
-735.25
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
3.65
16.9
Current ratio
5.39
5.11
5.39
5.42
6.01
4.01
17.78
Inventory turnover
—
—
0.19
0
—
—
—
Asset turnover
0.07
0.4
0.44
0.43
0.34
0.39
0.45
Solvency ratios
Debt to assets ratio
—
—
0.72
0.55
0.43
0.62
2.37
Debt to equity ratio
—
—
-1.09
-1.51
-13.91
-1.17
-6.21
Long term debt to total assets ratio
—
—
0.72
0.55
0.43
0.61
2.35
Long term debt to total equity ratio
—
—
-1.09
-1.51
-13.83
-1.16
-6.16
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-3.38
-3.4
EBIT per share
—
—
-3.84
-2.78
-2.55
-2.94
-2.96
EBITDA per share
—
—
-3.8
-2.76
-2.54
-2.94
-2.96
Total debt per share
—
—
4.28
3.42
2.86
2.57
10.31
Cash per share
—
—
4.38
4.91
5.64
2.5
12.77
Net current asset value per share
—
—
5.65
5.87
6.44
3.87
16.5
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
Working capital per share
—
—
4.6
4.79
5.37
2.9
12.77
Book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
Nouvelles
Le Zusduri d’UroGen affiche un taux sans événement de 72% à 24 mois
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma à la conférence TD Cowen : croissance stratégique et innovation
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation
Oppenheimer relève l’objectif de cours d’UroGen Pharma à 34$ sur les ventes de Zusduri
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales
Oppenheimer réitère sa recommandation sur UroGen Pharma suite aux solides ventes de Zusduri
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales
UroGen Pharma manque les prévisions de BPA et de chiffre d’affaires au T4 2025
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts
Palantir and AeroVironment among market cap stock movers on Monday
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates